Taken together, these results establish a novel immune feature‐based classification system that is able to predict recurrence‐free survival of prostate cancer patients, and the patients in the immune‐activated subgroup seem to be more responsive to anti‐PD‐1/PD‐L1 immunotherapy than other patients. This evidence concerns the gene PDCD1 and Familial prostate cancer.